PerkinElmer：从表型到靶点的药物研发流程
传统基于靶点（target-based）的药物研发流程耗费大量的时间（历时10年以上）和财力（数十亿美元），这种流程的成功率相当低，只在极少数的研发案例中出现能通过整个流程最终上市成为治疗疾病的药物，究其原因是从体外到体内的过程违背了药物发挥作用的基本原则，即只有在生理环境下有效果才算真正的效果。
近年来越来越多的药物研发转变为始于表型研究，继而转入靶点研究的新流程。这个流程的核心在于先确定候选药物能否引起细胞生理形态的改变，进而确认作用靶点，辅以正交实验的方法，通过大数据分析得到坚实可靠的结果。
在这次研讨会中，我们的专家将会在以下方面与您探讨：
(1).非标记检测在不用类型细胞表型研究中的应用
(2).细胞成像在表型研究中的应用
(3).靶点研究的最新实验方法
(4).通过正交方法获得坚实可靠的实验结果
PerkinElmer Company Overview
At PerkinElmer we're taking action to improve the health and safety of people and the environment. We're committed to transforming risk into safety, mystery into knowledge and ideas into action for healthier today and even better tomorrow. We are committed to delivering solutions that improve our customers' outcomes, advance human and environmental health technologies and, deliver shareholder value. Every day, we work together to ensure the way we do business is as meaningful as the solutions we provide.
Introducing the EnSight™ Multimode Plate Reader from PerkinElmer
PerkinElmer's EnSight Multimode Plate Reader is the first benchtop system to offer well-imaging alongside label-free and labeled detection technologies - for a whole new perspective on your research. For more information, please visit the EnSight website - http://bit.ly/T4IDPh
Pre-Clinical In Vivo Imaging Solutions from PerkinElmer
PerkinElmer offers a comprehensive portfolio of pre-clinical in vivo imaging systems and reagents. Find out more at http://bit.ly/1mnyvwF. Our pre-clinical imaging instruments include our highly published (over 4000 citations) IVIS Optical imaging systems, Quantum FX microCT which delivers high quality images at an x-ray dose low enough for longitudinal studies, and x-ray systems. We also offer a large portfolio of in vivo imaging reagents for most areas of research including cancer, infectious disease, stem cell, inflammation, toxicology/drug safety and more.